Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273958 | 0.87 | ADORA2A (0.56) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3269902 | 0.85 | ADORA2A (0.53) | ADORA2AADORA1PIK3R1PIK3CAADORA3 | |
| SCHEMBL3269811 | 0.83 | ADORA2A (0.47) | ADORA2AADORA1PIK3R1PIK3CAADORA3 | |
| SCHEMBL14002330 | 0.83 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL14002326 | 0.81 | ADORA2A (0.62) | ADORA2AADORA1PIK3R1PIK3CAADORA3 | |
| SCHEMBL3273966 | 0.71 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3272472 | 0.67 | ADORA2A (0.69) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3269076 | 0.67 | ADORA2A (0.71) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3267752 | 0.67 | ADORA2A (0.68) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3268277 | 0.67 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349857-B1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1349857-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055521-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | ADORA2A 14/4885ADORA1 17/4885PIK3R1 1417/4885 |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | OPRL1, CNR1, CNR2 | ADORA2A 13/4885ADORA1 28/4885PIK3R1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.